Literature DB >> 8168108

Allelotype of pancreatic adenocarcinoma.

A B Seymour1, R H Hruban, M Redston, C Caldas, S M Powell, K W Kinzler, C J Yeo, S E Kern.   

Abstract

Knowledge of the patterns of allelic loss has been useful in identifying the spectrum of the tumor suppressor genes involved in various tumor types. Such analyses in pancreatic carcinoma have been difficult due to the characteristic host desmoplastic reaction to the neoplasm. We have assembled the first allelotype of pancreatic adenocarcinoma, a survey for allelic loss among each chromosomal arm, using seven cryostat-dissected neoplasms. The fractional allelic loss in these seven neoplasms was 0.18, a value similar to that seen previously in colorectal carcinoma. Alleles of chromosome 18q (lost in five of six informative tumors) and of chromosome 17p (lost in four of five informative tumors) were commonly affected. Neither APC mutations (33 neoplasms), allelic shifts of dinucleotide repeats (26 neoplasms), nor immunohistochemical evidence of retinoblastoma protein underexpression (7 neoplasms) were found. Further evaluation of allelic loss in pancreatic cancer would benefit from improved methods for the analysis of lost genetic material which overcome the problems posed by the high admixture of nonneoplastic stromal and inflammatory cells in these tumors.

Entities:  

Mesh:

Year:  1994        PMID: 8168108

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

Review 1.  Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc.

Authors:  Anouchka Skoudy; Inmaculada Hernández-Muñoz; Pilar Navarro
Journal:  J Gastrointest Cancer       Date:  2011-06

Review 2.  Transgenic models of pancreatic cancer.

Authors:  Andrew M Lowy
Journal:  Int J Gastrointest Cancer       Date:  2003

3.  K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers.

Authors:  K Sugio; K Molberg; J Albores-Saavedra; A K Virmani; Y Kishimoto; A F Gazdar
Journal:  Int J Pancreatol       Date:  1997-06

Review 4.  An unfavourable prognosis for pancreatic cancer indicates fields of opportunity.

Authors:  W Greenhalf
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 5.  K-ras mutation and pancreatic adenocarcinoma.

Authors:  C Caldas; S E Kern
Journal:  Int J Pancreatol       Date:  1995-08

Review 6.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

7.  Plk4 is required for cytokinesis and maintenance of chromosomal stability.

Authors:  Carla O Rosario; Michael A Ko; Yosr Z Haffani; Rebecca A Gladdy; Jana Paderova; Aaron Pollett; Jeremy A Squire; James W Dennis; Carol J Swallow
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-26       Impact factor: 11.205

8.  Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy.

Authors:  Hyunki Kim; Guihua Zhai; Zhiyong Liu; Sharon Samuel; Nemil Shah; Emily E Helman; Joseph A Knowles; Cecil R Stockard; Naomi S Fineberg; William E Grizzle; Tong Zhou; Kurt R Zinn; Eben L Rosenthal
Journal:  Anticancer Drugs       Date:  2011-10       Impact factor: 2.248

9.  Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.

Authors:  M Schutte; L T da Costa; S A Hahn; C Moskaluk; A T Hoque; E Rozenblum; C L Weinstein; M Bittner; P S Meltzer; J M Trent
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

10.  TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells.

Authors:  Jimmy Y C Chow; Makiko Ban; Helen L Wu; Flang Nguyen; Mei Huang; Heekyung Chung; Hui Dong; John M Carethers
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-25       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.